Konrad Ng
Interventional Pain Management · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 1 carrier
- Office
- 1
- Since medical school
- 23 years
- Tufts University School of Medicine, 2003
Offices
1 location
Looking this up.
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plans that list them
10 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Konrad Ng’s office at (415) 737-0555 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A99746 · Current
Licensed to practise in California · since 2007 · expires 2027-04-30 · Tufts University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Forest Surgery Center LPAmbulatory Surgery Center · San Jose, CAOwner · accredited by JCAccreditation Renewed1 inspection, 1 with deficiencies · last 2012-09-18: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Physical Medicine and Rehabilitation - Pain Medicine
- American Board of Physical Medicine and Rehabilitation - Physical Medicine and Rehabilitation
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$44,377
Medicare paid this office $44,377 for 141 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 67 | $13,217 | $197 |
| Return visit (30+ min) | 48 | $8,119 | $118 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 37 | $5,691 | $124 |
| Long return visit (40+ min) | 20 | $4,025 | $161 |
| Short return visit (20+ min) | 35 | $3,927 | $85 |
See all 7 services
| New patient visit (60+ min) | 67 | $13,217 | $197 |
| Return visit (30+ min) | 48 | $8,119 | $118 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 37 | $5,691 | $124 |
| Long return visit (40+ min) | 20 | $4,025 | $161 |
| Short return visit (20+ min) | 35 | $3,927 | $85 |
| New patient visit (45+ min) | 28 | $3,825 | $137 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 12 | $748 | $47 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 17 | – | 23 | 37 | 23 | 46 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | – | – | 13 | 16 | – | 16 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
141 Original Medicare patients in 2024. Average age 76 · Women 60% · Also on Medicaid 12% · Health risk score 1.07. At or below the middle of the specialty; the typical interventional pain management clinician is at 1.37.
Conditions among them: High blood pressure 65% · Depression 23% · Coronary heart disease 20% · Diabetes 17% · Atrial fibrillation 17% · Cancer 16% · Chronic kidney disease 15% · Heart failure 11% · COPD 11%.
The office billed $162,480, Medicare allowed $57,928 and paid $44,377; for 345 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 141 | 345 | 76 | 1.07 | $162,480 | $44,377 |
| 2023 | 97 | 193 | 76 | 1.01 | $90,640 | $26,320 |
| 2022 | 108 | 248 | 75 | 1.17 | $123,870 | $32,519 |
| 2021 | 85 | 187 | 75 | 1.31 | $91,120 | $24,331 |
| 2020 | 90 | 324 | 69 | 1.41 | $56,838 | $27,233 |
| 2019 | 134 | 1,286 | 67 | 1.37 | $132,831 | $104,977 |
| 2018 | 67 | 221 | 70 | 1.30 | $35,115 | $19,110 |
| 2017 | 87 | 370 | 70 | 1.12 | $96,630 | $34,799 |
| 2016 | 85 | 397 | 70 | 1.12 | $111,070 | $32,214 |
| 2015 | 80 | 278 | 71 | 1.16 | $79,626 | $24,043 |
| 2014 | 173 | 927 | 74 | 1.08 | $183,802 | $68,240 |
| 2013 | 218 | 919 | 74 | 1.09 | $195,595 | $78,186 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| New patient visit (60+ min) | 37 | $7,101 | $192 |
| Return visit (30+ min) | 32 | $4,933 | $112 |
| New patient visit (45+ min) | 28 | $4,212 | $150 |
| Long return visit (40+ min) | 20 | $3,632 | $165 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 20 | $3,057 | $133 |
2022: 6 services
| New patient visit (60+ min) | 47 | $9,532 | $203 |
| Return visit (30+ min) | 33 | $6,380 | $114 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 34 | $4,430 | $120 |
| Long return visit (40+ min) | 24 | $4,372 | $168 |
| New patient visit (45+ min) | 23 | $3,395 | $148 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 14 | $777 | $49 |
2021: 6 services
| New patient visit (60+ min) | 41 | $7,452 | $182 |
| Return visit (30+ min) | 22 | $4,071 | $123 |
| Long return visit (40+ min) | 18 | $3,472 | $165 |
| New patient visit (45+ min) | 21 | $3,182 | $152 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 20 | $2,876 | $125 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 11 | $690 | $53 |
2020: 6 services
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 29 | $7,259 | $242 |
| Evaluation of psychological test, first hour | 35 | $3,635 | $71 |
| Return visit (30+ min) | 29 | $2,943 | $89 |
| Short return visit (20+ min) | 30 | $2,516 | $60 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 39 | $2,269 | $34 |
| New patient visit (60+ min) | 13 | $2,231 | $172 |
2019: 10 services
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 80 | $30,006 | $242 |
| Evaluation of psychological test, first hour | 60 | $16,038 | $103 |
| Return visit (30+ min) | 76 | $15,556 | $95 |
| Long return visit (40+ min) | 68 | $12,226 | $119 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 73 | $9,251 | $40 |
| Short return visit (20+ min) | 28 | $6,122 | $67 |
| New patient visit (60+ min) | 32 | $5,437 | $170 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 16 | $4,178 | $246 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $224 | $17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $18 | None |
2018: 4 services
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 17 | $4,356 | $242 |
| Long return visit (40+ min) | 21 | $4,341 | $132 |
| Return visit (30+ min) | 27 | $2,831 | $81 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $218 | $20 |
2017: 8 services
| Return visit (30+ min) | 41 | $10,760 | $97 |
| Short return visit (20+ min) | 37 | $5,161 | $60 |
| New patient visit (60+ min) | 16 | $3,072 | $192 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 16 | $2,489 | $131 |
| Long return visit (40+ min) | 14 | $2,324 | $137 |
| New patient visit (45+ min) | 13 | $1,971 | $152 |
| Radiological supervision and interpretation x-ray of covering of spinal cord | 19 | $761 | $36 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 15 | $183 | $11 |
2016: 7 services
| Return visit (30+ min) | 49 | $11,608 | $91 |
| Short return visit (20+ min) | 43 | $5,868 | $60 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 15 | $3,122 | $130 |
| Long return visit (40+ min) | 15 | $2,457 | $123 |
| New patient visit (60+ min) | 12 | $2,219 | $185 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 17 | $1,051 | $38 |
| Radiological supervision and interpretation x-ray of covering of spinal cord | 11 | $608 | $38 |
2015: 5 services
| Return visit (30+ min) | 37 | $5,894 | $100 |
| Short return visit (20+ min) | 41 | $4,828 | $64 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 14 | $1,998 | $133 |
| New patient visit (30+ min) | 13 | $1,316 | $101 |
| Radiological supervision and interpretation x-ray of covering of spinal cord | 15 | $1,248 | $73 |
2014: 10 services
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 75 | $13,282 | $133 |
| New patient visit (60+ min) | 63 | $11,485 | $182 |
| Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | 21 | $8,204 | $29 |
| Long return visit (40+ min) | 35 | $6,122 | $109 |
| Short return visit (20+ min) | 65 | $5,716 | $61 |
| Return visit (30+ min) | 38 | $5,004 | $96 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 54 | $4,600 | $58 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 47 | $2,465 | $39 |
| New patient visit (30+ min) | 11 | $1,003 | $91 |
| Muscle electrical test | 11 | $980 | $75 |
2013: 11 services
| New patient visit (60+ min) | 83 | $15,102 | $182 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 89 | $14,866 | $114 |
| Short return visit (20+ min) | 95 | $8,751 | $63 |
| Long return visit (40+ min) | 41 | $7,726 | $115 |
| Return visit (30+ min) | 53 | $6,292 | $89 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 70 | $5,842 | $53 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 59 | $2,963 | $38 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 25 | $2,411 | $78 |
| New patient visit (30+ min) | 17 | $1,604 | $94 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 12 | $1,594 | $94 |
| New patient visit (45+ min) | 11 | $1,556 | $141 |
Drugs they prescribed that Part D paid
$14,552
Pharmacies billed $14,552 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 38% of their Part D prescriptions (113 of 295) in 2024. At or below the middle of the specialty; the typical interventional pain management clinician is at 49%. Long-acting opioids: 12% of their opioid prescriptions.
279 generic and 16 brand-name prescriptions · $14,552 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtampza Er | 11 | $4,041 | $367 |
| Pregabalin | 59 | $943 | $16 |
| Gabapentin | 68 | $777 | $11 |
| Oxycodone | 34 | $553 | $16 |
| Hydrocodone-Acetaminophen | 18 | $358 | $20 |
See all 7 drugs
| Xtampza Er | 11 | $4,041 | $367 |
| Pregabalin | 59 | $943 | $16 |
| Gabapentin | 68 | $777 | $11 |
| Oxycodone | 34 | $553 | $16 |
| Hydrocodone-Acetaminophen | 18 | $358 | $20 |
| Tramadol | 36 | $136 | $4 |
| Methylprednisolone | 19 | $101 | $5 |
Year by year
| 2024 | 295 | 61 | 38% (113) | 5% | $14,552 |
| 2023 | 216 | 50 | 34% (73) | None | $14,549 |
| 2022 | 187 | 56 | 33% (61) | None | $7,033 |
| 2021 | 111 | 37 | 26% (29) | 0% | $2,366 |
| 2020 | 192 | 73 | 55% (105) | 17% | $14,756 |
| 2019 | 898 | 147 | 61% (543) | 16% | $69,002 |
| 2018 | 662 | 133 | 67% (442) | 9% | $36,791 |
| 2017 | 310 | 52 | 48% (148) | 11% | $25,807 |
| 2016 | 280 | 57 | 55% (155) | 15% | $21,160 |
| 2015 | 339 | 79 | 40% (137) | 14% | $22,021 |
| 2014 | 257 | 55 | 61% (157) | 11% | $16,116 |
| 2013 | 176 | 46 | 60% (105) | 11% | $9,275 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Pregabalin | 43 | $2,175 | $51 |
| Oxycodone | 25 | $956 | $38 |
| Naloxone | 12 | $944 | $79 |
| Gabapentin | 27 | $367 | $14 |
| Hydrocodone-Acetaminophen | 13 | $365 | $28 |
| Duloxetine | 13 | $191 | $15 |
| Methylprednisolone | 17 | $147 | $9 |
| Tramadol | 25 | $95 | $4 |
2022: 7 drugs
| Pregabalin | 24 | $1,542 | $64 |
| Hydrocodone-Acetaminophen | 18 | $449 | $25 |
| Methylprednisolone | 29 | $271 | $9 |
| Gabapentin | 12 | $181 | $15 |
| Duloxetine | 13 | $111 | $9 |
| Tramadol | 35 | $103 | $3 |
| Nabumetone | 11 | $101 | $9 |
2021: 5 drugs
| Naproxen | 13 | $566 | $44 |
| Pregabalin | 11 | $462 | $42 |
| Gabapentin | 25 | $418 | $17 |
| Hydrocodone-Acetaminophen | 16 | $145 | $9 |
| Tramadol | 13 | $23 | $2 |
2020: 5 drugs
| Belbuca | 13 | $5,131 | $395 |
| Hydrocodone-Acetaminophen | 44 | $1,009 | $23 |
| Morphine Sulfate | 11 | $550 | $50 |
| Morphine Sulfate Er | 11 | $493 | $45 |
| Gabapentin | 21 | $285 | $14 |
2019: 22 drugs
| Belbuca | 22 | $6,796 | $309 |
| Hydrocodone-Acetaminophen | 242 | $6,442 | $27 |
| Lyrica | 13 | $6,100 | $469 |
| Narcan | 26 | $3,496 | $134 |
| Fentanyl | 30 | $3,267 | $109 |
| Morphine Sulfate | 43 | $2,320 | $54 |
| Morphine Sulfate Er | 39 | $2,264 | $58 |
| Pregabalin | 15 | $2,171 | $145 |
| Buprenorphine | 14 | $1,325 | $95 |
| Oxycodone-Acetaminophen | 32 | $1,237 | $39 |
| Methadone | 31 | $1,038 | $33 |
| Oxycodone | 32 | $1,026 | $32 |
| Gabapentin | 51 | $741 | $15 |
| Cyclobenzaprine | 34 | $226 | $7 |
| Tramadol | 24 | $181 | $8 |
| Hydromorphone | 11 | $153 | $14 |
| Pantoprazole | 12 | $106 | $9 |
| Carisoprodol | 12 | $103 | $9 |
| Zolpidem | 18 | $93 | $5 |
| Alprazolam | 18 | $89 | $5 |
| Lorazepam | 17 | $77 | $5 |
| Ibuprofen | 13 | $72 | $6 |
2018: 12 drugs
| Oxycontin | 14 | $8,297 | $593 |
| Hydrocodone-Acetaminophen | 230 | $6,717 | $29 |
| Morphine Sulfate Er | 44 | $2,976 | $68 |
| Oxycodone-Acetaminophen | 41 | $2,528 | $62 |
| Fentanyl | 22 | $1,620 | $74 |
| Morphine Sulfate | 22 | $1,126 | $51 |
| Oxycodone | 34 | $891 | $26 |
| Gabapentin | 37 | $567 | $15 |
| Zolpidem | 17 | $142 | $8 |
| Cyclobenzaprine | 24 | $137 | $6 |
| Tramadol | 18 | $111 | $6 |
| Trazodone | 13 | $86 | $7 |
2017: 7 drugs
| Lyrica | 13 | $8,831 | $679 |
| Celecoxib | 26 | $1,662 | $64 |
| Hydrocodone-Acetaminophen | 71 | $1,055 | $15 |
| Gabapentin | 38 | $965 | $25 |
| Oxycodone | 21 | $441 | $21 |
| Tramadol | 23 | $113 | $5 |
| Acetaminophen-Codeine | 12 | $77 | $6 |
2016: 6 drugs
| Lyrica | 14 | $7,308 | $522 |
| Hydrocodone-Acetaminophen | 91 | $3,487 | $38 |
| Oxycodone-Acetaminophen | 37 | $1,729 | $47 |
| Celecoxib | 21 | $1,602 | $76 |
| Gabapentin | 40 | $698 | $17 |
| Tramadol | 11 | $47 | $4 |
2015: 6 drugs
| Oxycontin | 15 | $6,099 | $407 |
| Hydrocodone-Acetaminophen | 85 | $4,720 | $56 |
| Celecoxib | 13 | $1,117 | $86 |
| Gabapentin | 41 | $578 | $14 |
| Carisoprodol | 11 | $241 | $22 |
| Diazepam | 11 | $76 | $7 |
2014: 7 drugs
| Oxycontin | 14 | $4,958 | $354 |
| Hydrocodone-Acetaminophen | 55 | $2,788 | $51 |
| Oxycodone-Acetaminophen | 18 | $874 | $49 |
| Tramadol | 34 | $382 | $11 |
| Gabapentin | 30 | $362 | $12 |
| Nabumetone | 12 | $348 | $29 |
| Oxycodone | 14 | $288 | $21 |
2013: 5 drugs
| Oxycodone Hcl-Acetaminophen | 20 | $910 | $45 |
| Hydrocodone-Acetaminophen | 37 | $693 | $19 |
| Gabapentin | 14 | $315 | $22 |
| Tramadol | 22 | $274 | $12 |
| Naproxen | 20 | $182 | $9 |
Money from drug and device companies
$23 in 2025
| 2025 | 1 | 1 | None | $23 |
| 2023 | 2 | 2 | None | $111 |
| 2021 | 1 | 3 | None | $217 |
| 2019 | 4 | 6 | None | $93 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Saluda Medical Americas | Evoke | $23 | 1 payment
|
See the published payment
| Saluda Medical Americas | Meals · 2025-02-14 | Evoke | $23 |
See earlier years (2023, 2021, 2019)
2023: $111
| Edwards Lifesciences | None | $83 | 1 payment
|
| Boston Scientific | None | $29 | 1 payment
|
2021: $217
| Abbott Laboratories | Proclaim Ipg | $217 | 3 payments
|
2019: $93
| Pfizer | Embeda | $33 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $27 | 2 payments
|
| Teva Pharmaceuticals USA | Ajovy | $19 | 1 payment
|
| Shionogi | Symproic | $14 | 1 payment
|
Professional record
- NPI
- 1700074549
- Licence
- CA A99746California A99746: Current · expires 2027-04-30
- Trained
- Tufts University School of Medicine, 2003 · 23 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 208VP0014X (208VP0014X)
- Mailing address
- 2100 Webster St Ste 314, San Francisco, CA, 94115
- NPI first listed
- 2007-10-05
- NPI last updated
- 2020-04-08
- NPI record certified
- 2020-04-08
This is when the NPI record was last certified, not a medical board exam.